George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
This is from the RNS of 14/12, we are nearly 4 months in;
“ A significant factor in Nuformix's decision to enter into the Subscription is that the Sharing Agreements provide the opportunity for the Company to benefit from positive future share price performance. There is no upper limit placed on the additional proceeds receivable by the Company as part of the monthly settlements and the amount available in subsequent months is not affected. Whilst the Company notes the corresponding risk that a fall in Nuformix's share price could reduce the amount of proceeds received, as explained below, the Directors expect A significant factor in Nuformix's decision to enter into the Subscription is that the Sharing Agreements provide the opportunity for the Company to benefit from positive future share price performance. There is no upper limit placed on the additional proceeds receivable by the Company as part of the monthly settlements and the amount available in subsequent months is not affected. Whilst the Company notes the corresponding risk that a fall in Nuformix's share price could reduce the amount of proceeds received, as explained below, the Directors expect the Company's pre-clinical progress of its products and business development strategy to make considerable positive advances over the 20-month term of the Sharing Agreements. If these advances are successful, and if the success of these advances is reflected in Nuformix's share price, the Company expects the proceeds to be received back from Lanstead to exceed the amount pledged under the Sharing Agreements although there can be no guarantee that this outcome will occur. the Company's pre-clinical progress of its products and business development strategy to make considerable positive advances over the 20-month term of the Sharing Agreements. If these advances are successful, and if the success of these advances is reflected in Nuformix's share price, the Company expects the proceeds to be received back from Lanstead to exceed the amount pledged under the Sharing Agreements although there can be no guarantee that this outcome will occur.”
CPI dropped 6m shares between 17/11 and 14/2, last TR1 had 26m. 21m is 3%. Not long to go.
Strategic?
Seems there have been a number of studies, here is one from Iran
Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial
By DocWire News Featured Reading - March 27, 2022
This article was originally published here
Arch Med Res. 2022 Mar 14:S0188-4409(22)00024-8. doi: 10.1016/j.arcmed.2022.03.002. Online ahead of print.
ABSTRACT
BACKGROUND: Tranilast is a potential NLRP3 inflammasome inhibitor that may relieve progressive inflammation due to COVID-19.
AIM OF THE STUDY: To evaluate the therapeutic effects of Tranilast in combination with antiviral drugs in non-ICU-admitted hospitalized patients with COVID-19.
METHODS: This study was an open-label clinical trial that included 72 hospitals admitted patients with severe COVID-19 at Razi Hospital, Ahvaz, Iran, from July 2020-August 2020. These patients were randomly assigned in a 1:1 ratio to control (30) and intervention groups (30). Patients in the control group received antiviral therapy, while patients in the intervention group received Tranilast (300 mg daily) in addition to the antiviral drugs for Seven days. The collected data, including the expression of inflammatory cytokine, laboratory tests, and clinical findings, was used for intragroup comparisons.
RESULTS: The intervention group showed significantly lower levels of NLR (p = 0.001), q-CRP (p = 0.002), IL-1 (p = 0.001), TNF (p = 0.001), and LDH (p = 0.046) in comparison with the control group. The effect of intervention was significant in increasing the o2 saturation (F = 7.72, p = 0.007). Long hospitalization (four days or above) was 36.6% in the Tranilast and 66.6% in the control group (RR = 0.58; 95% CI: 0.38-1.06, p = 0.045). In the Tranilst and control groups, one and four deaths or hospitalization in ICU were observed respectively (RR = 0.31; 95% CI: 0.03-2.88, p = 0.20).
CONCLUSIONS: Tranilast might be used as an effective and safe adjuvant therapy and enhance the antiviral therapy’s efficacy for managing patients with COVID-19.
What value do you put on a 20 year patent?
From market watch
SVB Leerink: AstraZeneca's Lynparza could bring in $9.7 billion in sales by 2028
Published: March 14, 2022 at 10:42 a.m. ET
By Jaimy Lee
The Food and Drug Administration's approval on Friday of AstraZeneca's Lynparza as a treatment for some people with early-stage breast cancer could bring in $1.5 billion in annual revenue for the company. U.S.-listed shares of AstraZeneca AZN AZN were up 1.5% in trading on Monday. SVB Leerink analyst Andrew Berens told investors in a note on Monday that he expects rapid adoption of the therapy among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer who have previously received treatment. Lynparza is already approved as a treatment for ovarian cancer; it brought in $2.7 billion in revenue in 2022. Berens expects the drug to generate $9.7 billion in sales by 2028 when taking into account the breast-cancer approval and positive clinical data among prostate-cancer patients.
Soup I find that the RNS use of English to be inconsistent at best the use of the English language is poor an inaccurate , so it is difficult to know exactly what is going on. The RNS re DG was appointed not LSHS (might have already been sold) or was it LSHS and the RNS was wrong. It is hard to work out. The Dec placing RNS said the money was for business development of both 002 and 004, the 8/2 RNS continued progress in both 002 and 004 and no update, the appointment of DG (not LSHS) only for BD of 002, not 004. Finally the last RNS says they continue to investigate commercial opportunities for 004?
What about an IP sale of 002 and 004 and the shell bought by Oxilio so they get a listing
Sorry to hear about Jay12 especially the loss for a young family
Thanks M, it will be interesting to see if AZ will want a competitor to have a 20 year patent on an improved version
The website needs updating as 004 refers to an undisclosed oncology drug, well it was disclosed when the patent application was published. Soup never could understand the idiots just coming to rubbish a share just trying to destroy the lives of every shareholder shameful existence they get locked up if they steal physical assets.
It is understandable why this is a blockbuster drug a bit of background information which is most unpleasant
Breast cancer is the most commonly diagnosed cancer worldwide with an estimated 2.3 million patients diagnosed in 2020. Almost 91% of all breast cancer patients in the U.S. are diagnosed at an early stage of disease, and germline BRCA mutations are found in approximately 5-10% of all breast cancer patients.
This is the head of r&d at AZ responsible for drug development wonder if she ever worked with AB
https://www.astrazeneca.com/our-company/leadership/susan-galbraith.html
Well done Soup, think Bod would have RNS this first.
Particularly relevant this month due to news the value should have increased;
Last week, LYNPARZA was approved by the U.S. Food and Drug Administration for the adjuvant treatment of patients with gBRCAm, HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy based on results from the OlympiA trial. LYNPARZA is also approved in the U.S., EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative metastatic breast cancer previously treated with chemotherapy and, if hormone receptor-positive, endocrine therapy if appropriate based on results from the Phase 3 OlympiAD trial. In the EU and Japan, this indication also includes patients with locally advanced breast cancer.
Maybe the clue is the fact that the lead drugs for NFX is 002 and 004
Oxilio is exploring new areas with 001 not its original use, therefore is unproven in both oncology and CINV, so is definitely not a blockbuster replacement, and therefore has a much lower value. 004 on the other hand in its original form has in excess of $1bn annual sales so is already a blockbuster drug and 004 is an improvement on the original.
FX they started with oncology and yes still have that license but their focus seems to have switched to CINV maybe DGs influence as per last Oxilio RNS when we found out. 004 is already oncology based and linked to a patent cliff so much more interesting
Thought Oxilio had gone the CINV route as oncology was less of an option. 004 for oncology much more interesting.
Interesting article “ The hottest markets to jump into? Moody’s expects it will be oncology, immunology and gene therapy ….
Our report dives into what some of the most go to exposed companies are doing to prepare for their looming patent cliffs. The findings are based on information from Moody’s Investment Services, as well as company filings, investor calls, FDA records and more.
https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade